Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

T. Li, Bob; F. Smit, Egbert; Goto, Yasushi; Nakagawa, Kazuhiko; Udagawa, Hibiki; Mazières, Julien; Nagasaka, Misako; Bazhenova, Lyudmila; Saltos, Andreas; Felip, Enriqueta; M. Pacheco, Jose; Pérol, M.; Paz‐Ares, Luis; Saxena, Kapil; Shiga, Ryota; Cheng, Yingkai; Acharyya, Suddhasatta; Vitazka, Patrik; Shahidi, Javad; Planchard, David; A. Jänne, Pasi

doi:10.1056/nejmoa2112431

Public

Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Sep 18, 2021

Authors:

Bob T. Li

Egbert F. Smit

Yasushi Goto

Abstract

BACKGROUND: -mutant NSCLC have not been investigated extensively. METHODS: -mutant NSCLC that was refractory to standard treatment. The primary outcome was objective response as assessed by independent central review. Secondary outcomes included the duration of response, progression-free survival, o...

Subject

Trastuzumab

Antibody-drug conjugate

Epidermal growth factor receptor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!